PURPOSE OF REVIEW: Efforts to discover modalities and pathophysiologies that might afford successful neurorescue, neurorestoration, and neuroprotection of cells of the central nervous system have focused on processes that affect the central nervous system proper, that is, the brain. Often overlooked in the search for neural protection is the fact that the mammalian optic nerve behaves in many ways as an integral part of the central nervous system. As such, the eye--the optic nerve and retina--affords an ideal clinical model for neuroprotection and neuroprotective agents. Glaucomatous optic neuropathy is the most prevalent of all adult optic neuropathies, and offers an ideal primate and lower mammalian animal model for investigations of neuroprotection. RECENT FINDINGS: This is especially compelling because while recent studies in glaucoma have shown reduction of intraocular pressure (IOP) to be an effective modality in the treatment of glaucomatous optic neuropathy, not all patients respond to or can achieve meaningful IOP reductions. Therefore much attention has now been focused on neuroprotection as a strategy in therapies for glaucomatous optic neuropathy as a means of preserving retinal ganglion cells and their axonal projections. SUMMARY: This review discusses the latest studies on various mechanisms of neuroprotection in the treatment of glaucomatous optic neuropathy.
PURPOSE OF REVIEW: Efforts to discover modalities and pathophysiologies that might afford successful neurorescue, neurorestoration, and neuroprotection of cells of the central nervous system have focused on processes that affect the central nervous system proper, that is, the brain. Often overlooked in the search for neural protection is the fact that the mammalian optic nerve behaves in many ways as an integral part of the central nervous system. As such, the eye--the optic nerve and retina--affords an ideal clinical model for neuroprotection and neuroprotective agents. Glaucomatous optic neuropathy is the most prevalent of all adult optic neuropathies, and offers an ideal primate and lower mammalian animal model for investigations of neuroprotection. RECENT FINDINGS: This is especially compelling because while recent studies in glaucoma have shown reduction of intraocular pressure (IOP) to be an effective modality in the treatment of glaucomatous optic neuropathy, not all patients respond to or can achieve meaningful IOP reductions. Therefore much attention has now been focused on neuroprotection as a strategy in therapies for glaucomatous optic neuropathy as a means of preserving retinal ganglion cells and their axonal projections. SUMMARY: This review discusses the latest studies on various mechanisms of neuroprotection in the treatment of glaucomatous optic neuropathy.
Authors: Kyung-A Kim; Sang Min Kim; Suk Woo Kang; Sang Il Jeon; Byung Hun Um; Sang Hoon Jung Journal: Mar Biotechnol (NY) Date: 2012-05-18 Impact factor: 3.619
Authors: Georg Mossböck; Martin Weger; Christoph Faschinger; Christine Zimmermann; Otto Schmut; Wilfried Renner; Yosuf El-Shabrawi Journal: Mol Vis Date: 2010-08-28 Impact factor: 2.367
Authors: Ireneusz Majsterek; Lukasz Markiewicz; Karolina Przybylowska; Mira Gacek; Anna K Kurowska; Anna Kaminska; Jerzy Szaflik; Jacek P Szaflik Journal: Med Sci Monit Date: 2011-07
Authors: Gala Beykin; Anthony M Norcia; Vivek J Srinivasan; Alfredo Dubra; Jeffrey L Goldberg Journal: Prog Retin Eye Res Date: 2020-07-10 Impact factor: 21.198
Authors: Tobias Frank; Johannes C M Schlachetzki; Bettina Göricke; Katrin Meuer; Gundula Rohde; Gunnar P H Dietz; Mathias Bähr; Armin Schneider; Jochen H Weishaupt Journal: BMC Neurosci Date: 2009-05-14 Impact factor: 3.288
Authors: Andreas Borkenstein; Christoph Faschinger; Richard Maier; Martin Weger; Anna Theisl; Ulrike Demel; Winfried Graninger; Holzer Irene; Georg Mossböck Journal: Mol Vis Date: 2013-11-16 Impact factor: 2.367